Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. It has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, and pain. The company’s products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorder; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux disease; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorder, and depressive disorder; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as product filed with the FDA comprise Pristiq, a tablet for depression. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Its late stage development product includes Coreg CR, a capsule for heart failure and hypertension; and phase I clinical trial products include Lyrica, a capsule for Neuropathic pain and Oxycodone Hydrochloride, a controlled release capsule for pain. The company’s non-generic products under development include Rexista, an oral formulation for pain relief, and Pregabalin, an extended release capsule for neuropathic pain. The company was founded in 1998 and is based in Toronto, Canada.